Serological, genetic and clinical associations with increased health‐care resource utilization in inflammatory bowel disease

Serological, genetic and clinical associations with increased health‐care resource utilization... INTRODUCTIONInflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is an immune‐mediated condition driven by chronic inflammation of the intestinal mucosa. It is characterized by a highly variable clinical course associated with periods of remission and severe relapses. Approximately 1.4 million people are currently affected by IBD in the USA. In North America the prevalence of CD ranges from 26 to 199 cases per 100 000 individuals and that of UC ranges from 37 to 246 cases per 100 000 individuals.Most commonly diagnosed in late adolescence and early adulthood, IBD is an incurable disease that frequently commits patients to lifelong medical care that often results in substantial medical expenses. In 2004 the mean annual cost of treatment was $8265 per patient for CD and $5066 per patient for UC in the USA. The total annual disease‐attributable direct cost of IBD in the USA is estimated to be $6.3 billion ($3.6 billion for CD and $2.7 billion for UC). Most of the costs occur during the first year of diagnosis. Surgery and hospitalizations were previously the primary drivers of cost but they have recently played a smaller role since the introduction of biologic agents. In 2014, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Digestive Diseases Wiley

Serological, genetic and clinical associations with increased health‐care resource utilization in inflammatory bowel disease

Loading next page...
 
/lp/wiley/serological-genetic-and-clinical-associations-with-increased-health-Dblz7FkCMg
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd
ISSN
1751-2972
eISSN
1751-2980
D.O.I.
10.1111/1751-2980.12566
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONInflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is an immune‐mediated condition driven by chronic inflammation of the intestinal mucosa. It is characterized by a highly variable clinical course associated with periods of remission and severe relapses. Approximately 1.4 million people are currently affected by IBD in the USA. In North America the prevalence of CD ranges from 26 to 199 cases per 100 000 individuals and that of UC ranges from 37 to 246 cases per 100 000 individuals.Most commonly diagnosed in late adolescence and early adulthood, IBD is an incurable disease that frequently commits patients to lifelong medical care that often results in substantial medical expenses. In 2004 the mean annual cost of treatment was $8265 per patient for CD and $5066 per patient for UC in the USA. The total annual disease‐attributable direct cost of IBD in the USA is estimated to be $6.3 billion ($3.6 billion for CD and $2.7 billion for UC). Most of the costs occur during the first year of diagnosis. Surgery and hospitalizations were previously the primary drivers of cost but they have recently played a smaller role since the introduction of biologic agents. In 2014,

Journal

Journal of Digestive DiseasesWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off